US20230390348A1 - Composition for enhancing immune checkpoint blockade therapy - Google Patents
Composition for enhancing immune checkpoint blockade therapy Download PDFInfo
- Publication number
- US20230390348A1 US20230390348A1 US18/236,035 US202318236035A US2023390348A1 US 20230390348 A1 US20230390348 A1 US 20230390348A1 US 202318236035 A US202318236035 A US 202318236035A US 2023390348 A1 US2023390348 A1 US 2023390348A1
- Authority
- US
- United States
- Prior art keywords
- composition
- lactic acid
- acid bacterium
- immune checkpoint
- blockade therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 74
- 230000005746 immune checkpoint blockade Effects 0.000 title claims abstract description 44
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 136
- 229920002444 Exopolysaccharide Polymers 0.000 claims abstract description 77
- 239000004310 lactic acid Substances 0.000 claims abstract description 68
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 68
- 241000894006 Bacteria Species 0.000 claims abstract description 67
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims abstract description 12
- 241000186660 Lactobacillus Species 0.000 claims abstract description 11
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 claims abstract 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims description 35
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 35
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 31
- 230000001965 increasing effect Effects 0.000 claims description 23
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 21
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 21
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 235000015140 cultured milk Nutrition 0.000 claims description 13
- 229940039696 lactobacillus Drugs 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 38
- 235000013305 food Nutrition 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 26
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 21
- 238000000855 fermentation Methods 0.000 description 15
- 230000004151 fermentation Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 235000013618 yogurt Nutrition 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- -1 antibiotic Substances 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 229940126546 immune checkpoint molecule Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 238000002224 dissection Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 238000000968 medical method and process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 229910018994 (KOHYO) No Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010065713 Gastric Fistula Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000037977 Immune checkpoint ligands Human genes 0.000 description 1
- 108091008029 Immune checkpoint ligands Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011306 frozen processed food Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Definitions
- the present invention relates to a composition comprising a culture of a lactic acid bacterium for enhancing an immune checkpoint blockade therapy.
- the immune checkpoint blockade therapy is a therapy consisting of canceling suppression of activation of immunocytes including T lymphocytes by inhibiting transfer of immunosuppression signals by immune checkpoint molecules, and thereby increasing patient's immune activity to obtain an antitumor effect.
- immunity checkpoint blockades inhibitors
- PD-1 Programmed Death-1) blocking antibody agents
- CTLA-4 Cytotoxic T Lymphocyte-associated Antigen 4
- Patent document 1 discloses a combination of one or more kinds of anticancer antibodies, and a specific immuno-adjuvant compound for treatment of cancer, and describes that this combinatory drug can be administered further in combination with an antibody that blocks an immunosuppression function.
- Patent document 2 discloses a peptide consisting of a straight chain sequence of nine amino acids as a compound to be used for treatment of a tumor by being administered in combination with, sequentially with, or separately from an immunity checkpoint blockade.
- Patent document 3 discloses a concomitant use of a compound that blocks an interaction between the signal regulatory protein alpha (SIRPa) and at least one of the ligands thereof (for example, anti-SIRPa antibody) with a second therapeutic drug, which is for use in a treatment of an arbitrary pathological condition that can be improved or prevented by differentiation of myeloid-derived suppressor cells (MDSC) into non-suppressor cells.
- SIRPa signal regulatory protein alpha
- MDSC myeloid-derived suppressor cells
- the second therapeutic drug can be selected from the group consisting of chemotherapeutic drug, radiotherapy, surgical operation, immunotherapy drug, antibiotic, and probiotics.
- lactic acid bacteria produce various substances in the fermentation processes thereof, and one class of them is constituted by extracellular polysaccharides (exopolysaccharides. EPSs).
- EPSs extracellular polysaccharides
- the immune checkpoint blockade therapy retracts tumors by activating the patients' own immunity, the patients suffer from less burden compared with the conventional surgical resection and radiotherapy. If there is a composition that can enhance the effect of this therapy, it is much more desirable.
- the present invention provides the followings.
- the present invention also provides the followings.
- an immune checkpoint blockade therapy can be effectively enhanced.
- CCR6-positive CD8+T lymphocytes can also be increased.
- FIG. 1 A The tumor volumes observed for the CTLA-4 blockade therapy group (data for all the individuals). Black solid lines indicate the data for the yogurt-administered mice, and gray broken lines indicate the data for the control mince. The Student's t-test was performed for the data obtained at the time of the last tumor volume measurement, and p values were obtained.
- FIG. 1 B The tumor volumes observed for the CTLA-4 blockade therapy group (data for the lower half of the individuals arranged in the order of tumor volume, large to small, for both the yogurt-administered group and the control group). Black solid lines indicate the data for the yogurt-administered mice, and gray broken lines indicate the data for the control mice.
- the Student's t-test was performed for the data obtained at the time of the last tumor volume measurement, and p values were obtained.
- FIG. 1 C CCR6-positive ratios of the CD8+T lymphocytes. The results are shown in the form of average f SE.
- FIG. 1 D The tumor volumes observed for the PD-1 blockade therapy group. Black solid lines indicate the data for the yogurt-administered mice, and gray broken lines indicate the data for the control mice.
- FIG. 2 A The tumor volumes observed for the mice (data for all the individuals). Black solid lines indicate the data for the EPS-administered mice, and gray broken lines indicate the data for the control mice.
- the Student's t-test was performed for the data obtained at the time of the last tumor volume measurement, and p values were obtained.
- FIG. 2 B The tumor volumes observed for the mice (data for the lower half of the individuals arranged in the order of tumor volume, large to small, for both the EPS-administered group and the control group). Black solid lines indicate the data for the EPS-administered mice, and gray broken lines indicate the data for the control mice.
- the Student's t-test was performed for the data obtained at the time of the last tumor volume measurement, and p values were obtained.
- FIG. 3 CCR6-positive ratios of the TG40 cells (%).
- the CCR6-positive ratio significantly increased (p ⁇ 0.001) compared with the control in which EPS was not added (Student's t-test).
- the present invention relates to a composition for enhancing an immune checkpoint blockade therapy, which uses an exopolysaccharide (EPS) produced by a lactic acid bacterium as an active ingredient.
- EPS exopolysaccharide
- composition of the present invention contains EPS of a lactic acid bacterium as an active ingredient.
- lactic acid bacteria is a general term indicating microorganisms that utilize glucose to produce lactic acid at a yield of 50% or higher based on the saccharide, and as for their physiological characteristics, they are gram-positive cocci or bacilli, and show such characteristics as no motility, no sporulation ability, and catalase negativity. From ancient times, lactic acid bacteria have been eaten in every corner of the world as those contained in fermented milk, and so forth, and can be considered to be extremely safe microorganisms. The lactic acid bacteria are classified into a plurality of genera. EPS of a lactic acid bacterium contained in the composition of the present invention is preferably one produced by a Lactobacillus lactic acid bacterium, which is classified into the genus Lactobacillus.
- Examples of the genus Lactobacillus include, for example, those of Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus plantarum , and so forth.
- lactic acid bacteria classified into the bulgaricus species also referred to as bulgaricus bacteria
- those classified into Lactobacillus delbrueckii subsp. bulgaricus are more preferred.
- the lactic acid bacterium is Lactobacillus delbrueckii subsp. bulgaricus OLL1073 R-1 strain (accession number FERM BP-10741) (also referred to as “ Lactobacillus delbrueckii subsp. bulgaricus R-1 strain”).
- Lactobacillus delbrueckii subsp. bulgaricus R-1 strain was deposited at the independent administrative agency. National Institute of Technology and Evaluation, International Patent Organism Depository (IPOD, NITE, #120, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba-ken, 292-0818, Japan) as an international deposition based on the provisions of the Budapest Treaty (depositor, Meiji Co., Ltd.; deposition date. Nov. 29, 2006; accession number. FERM BP-10741).
- EPS to be used in the composition of the present invention as an active ingredient is not particularly limited, so long as it is an EPS that is produced by a lactic acid bacterium (preferably a Lactobacillus lactic acid bacterium classified into the genus Lactobacillus ) and provides the objective effect.
- EPSs produced by lactic acid bacteria are structurally classified into homopolysaccharides and heteropolysaccharides (for example, those constituted by galactose and glucose), and may be modified by phosphorylation, sulfation, or the like, and those of both types can be used as the active ingredient of the composition of the present invention.
- One of the preferred examples is an acidic EPS containing many phosphate groups. Examples of such EPS are EPSs produced by the Lactobacillus delbrueckii subsp. bulgaricus R-1 strain (refer to Patent document 6 mentioned above).
- EPS of a lactic acid bacterium contained in the composition of the present invention may be contained as a lactic acid bacterium fermentation product.
- the lactic acid bacterium fermentation product may be a fermentation product itself produced by a lactic acid bacterium, or a processed product thereof.
- the lactic acid bacterium fermentation product may be, for example, fermented milk (specifically, yogurt etc.).
- Examples of the processed product thereof include, for example, roughly purified product, culture filtrate or culture supernatant obtained from the fermentation product by removing cells using filtration, centrifugation, or membrane separation, concentrate obtained by concentrating the culture filtrate or culture supernatant, and dried product of the concentrate.
- EPS of a lactic acid bacterium As for the production method of EPS of a lactic acid bacterium, Patent document 6 mentioned above, and so forth can be referred to.
- fermented milk containing EPS can be produced by adding a lactic acid bacterium that produces EPS as a starter to raw material milk, and allowing fermentation so that EPS is produced in the fermentation product.
- the conditions for the fermentation such as type of raw material milk, fermentation temperature, and fermentation time, are not particularly limited, so long as the lactic acid bacterium used can produce EPS, and those skilled in the art can appropriately set them.
- the composition of the present invention can be used in order to enhance an immune checkpoint blockade therapy.
- the expression of to enhance an immune checkpoint blockade therapy means to make the effect of the immune checkpoint blockade therapy to be obtained earlier, to increase the effect of the immune checkpoint blockade therapy, to increase response rate for the immune checkpoint blockade therapy, to make the effect of the immune checkpoint blockade therapy to be obtained with a lower dose of the immune checkpoint blockade, or the like, when the composition of the present invention is used in combination with the immune checkpoint blockade therapy.
- Examples of the effect of an immune checkpoint blockade therapy include, for example, shrink of cancer by death of cancer cells (decrease of tumor volume), delay of growth of cancer (suppression of increase of tumor volume), cure of cancer, prevention of metastasis or recurrence of cancer, and death of possible metastasized cancer cells.
- the immune checkpoint molecules constitute a group of molecules that suppress immune responses to self in order to maintain immunological homeostasis, and at the same time, suppress excessive immunoreactions. Although they originally exist in order to suppress excessive activation of the immunocytes including T lymphocytes, and prevent attacks against self, cancer cells utilize them in a carcinogenic process in order to avoid attacks by the immune system and thereby grow. Until now, various immune checkpoint molecules and ligands thereof have been identified.
- the immune checkpoint molecules include PD-1, CTLA-4, TIM-3, BTLA, and LAG-3/TCR
- the composition of the present invention can be used in a therapy concerning inhibition by any of such immune checkpoint molecules.
- Especially preferred examples of the therapy include a therapy using a CTLA-4 blockade and a therapy using a PD-1 blockade.
- CTLA-4 blockade include ipilimumab (Yervoy), avelumab, and atezolizumab
- examples of the PD-1 blockade include nivolumab (Opdivo), pembrolizumab (Keytruda), and pembrolizumab.
- the composition of the present invention can be used for any immune checkpoint blockade therapy using any of these.
- the lowness of response rate for immune checkpoint blockade therapies has constituted a serious problem.
- the main cause for that is that many checkpoints (brakes) occur until the immune system of patient functions and cancer cells are actually injured. That is, even if one of the brakes can be eliminated with one kind of immunity checkpoint blockade, there are often still other brakes, and therefore sufficient curative effect cannot be observed in many cases.
- the composition of the present invention has an action of increasing a certain kind of cytotoxic T lymphocytes (CCR6-positive CD8+T lymphocytes).
- composition of the present invention can also be expected to compensate the lowness of the response rate for immune checkpoint blockade therapies.
- cancers to which immune checkpoint blockade therapy is applied include malignant melanoma, non-small cell lung cancer, renal cell cancer, Hodgkin's lymphoma, head and neck cancer, gastric cancer, urinary tract epithelial cancer, Merkel cell cancer, and so forth.
- the composition of the present invention can be used for an immune checkpoint blockade therapy for any of these.
- the composition of the present invention has an action of helping the action of CCR6-positive CD8+T lymphocytes to recognize and kill cells as foreign matter for the subject (cancer cells, virus-infected cells, etc.) (for example, increasing the T lymphocytes, promoting guidance to foreign matter, etc.). Therefore, the composition of the present invention can be used for increasing CCR6-positive CD8+T lymphocytes in the body of a subject, and it can be used for increasing CCR6-positive CD8+T lymphocytes especially in a tumor in the body of the subject.
- the CCR6-positive ratio means a ratio of CCR6-positive cells among T lymphocytes, unless especially indicated.
- the CCR6-positive ratio can be obtained as (number of CD3+, CD8+, and CCR6-positive cells)/(number of CD3+ and CD8+ cells), and for an experiment system using TG40, the CCR6-positive ratio can be obtained as (number of CCR6-positive cells)/(total number of TG40 cells).
- composition of the present invention can be used even for a case that the immune checkpoint blockade therapy is carried out together with another therapy for treatment of cancer.
- another therapy include operation (surgical treatment), therapy using a drug other than immune checkpoint blockade (for example, antimetabolite, alkylating agent, anticancerous antibiotic, microtubule inhibitor, etc.), radiotherapy, hematopoietic stem cell transplantation after a pre-transplantation treatment consisting of massive chemotherapy, systemic radiotherapy, or the like, immunotherapy other than immune checkpoint blockade therapy (for example, cytokine therapy, administration of an immunostimulator, immunocyte transplantation, etc.), alternative therapy for cancer using health food or supplement, and so forth.
- a drug other than immune checkpoint blockade for example, antimetabolite, alkylating agent, anticancerous antibiotic, microtubule inhibitor, etc.
- radiotherapy hematopoietic stem cell transplantation after a pre-transplantation treatment consisting of massive chemotherapy, systemic radiotherapy,
- the composition of the present invention can be in the form of a food composition or pharmaceutical composition.
- Food and drug are not limited to those for humans, and may be those for animals other than human, unless especially indicated.
- the food may be a common food, functional food, or nutritional composition, or a therapeutic diet (diet for the purpose of treatment, for which a medical practitioner writes a dietary prescription, and which is cooked by a dietitian or the like according to the prescription), dietetic food, ingredient-modified food, care food, or treatment-supporting food, unless especially indicated.
- the food is not limited to a solid food, but it may be a food in the form of liquid, for example, drink, drinkable preparation, liquid food, or soup, unless especially indicated.
- Functional food refers to a food that can give a predetermined functionality to a living body, and includes health foods at large, such as foods for specified health uses (abbreviated as “Tokuho” in Japanese, including conditional foods for specified health use), foods with function claims, foods with health claims including foods with nutrient function claims, foods for special dietary uses, supplements (for example, those of various kinds of dosage forms such as tablet, coated tablet, sugar-coated tablet, capsule and solution), and cosmetic food (for example, diet foods).
- the “functional foods” include health foods to which the health claim based on the food standards of CODEX (JOINT FAO/WHO FOOD STANDARDS PROGRAMME CODEX ALIMENTARIUS COMMISSION) is applied.
- composition of the present invention is suitable to be ingested by or administered to a subject who or which receives an immune checkpoint blockade therapy, or a subject who or which is planned to receive an immune checkpoint blockade therapy.
- composition of the present invention may be administered parenterally, for example, by tube administration (by gastric fistula, cecal fistula, or the like), or may be administered nasally or orally, it is preferably orally administered.
- Content of EPS of a lactic acid bacterium in the composition of the present invention may be such an amount that the objective effect can be exhibited.
- the dose or ingestion amount of the composition can be appropriately determined in consideration of various factors such as age, weight, and condition of the subject, the daily administration or ingestion amount of EPS of a lactic acid bacterium may be, for example, 0.1 mg or larger, and it is preferably 0.6 mg or larger, more preferably 3 mg or larger.
- the maximum daily amount of EPS may be 480 mg or smaller, and it is preferably 360 mg or smaller, more preferably 180 mg or smaller, particularly preferably 90 mg or smaller.
- the amount of EPS of a lactic acid bacterium per one time of administration or meal i.e., dose of EPS for single administration or meal, may be, for example, 0.03 mg or larger, and it is preferably 0.2 mg or larger, more preferably 1 mg or larger.
- the maximum amount of the same may be 160 mg or smaller, and it is preferably 120 mg or smaller, more preferably 60 mg or smaller, particularly preferably 30 mg or smaller.
- the daily amount of the fermented milk may be, for example, 10 g or larger, and it is preferably 30 g or larger, more preferably 60 g or larger.
- the maximum amount of the same may be, for example, 1500 g or smaller, and it is preferably 1200 g or smaller, more preferably 600 g or smaller.
- the amount of fermented milk for one time of administration or meal. i.e., dose for single administration or meal, may be, for example, 3 g or larger, and it is preferably 10 g or larger, more preferably 20 g or larger.
- the maximum amount of the same may be, for example, 800 g or smaller, and it is preferably 400 g or smaller, more preferably 200 g or smaller.
- the composition may be administered or ingested one time per day, or may be administered a plurality of times per day, for example, at every meal, i.e., three times a day.
- the composition uses EPS of a lactic acid bacterium, which has been abundantly used in foods for many years, as the active ingredient. Therefore, the composition of the present invention can be ingested repetitively, or over a long period of time, and it may be continuously administered or ingested over, for example, one week or longer, preferably four weeks or longer.
- composition of the present invention may contain another active ingredient or nutritional ingredient acceptable for foods or drugs.
- an ingredient include amino acids (for example, lysine, arginine, glycine, alanine, glutamic acid, leucine, isoleucine, and valine), saccharides (glucose, sucrose, fructose, maltose, trehalose, erythritol, maltitol, paratinose, xylitol, and dextrin), electrolytes (for example, sodium, potassium, calcium and magnesium), vitamins (for example, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, biotin, folic acid, pantothenic acid, and nicotinic acid), minerals (for example, copper, zinc, iron, cobalt, and manganese), antibiotics, dietary fibers, proteins, lipids, and so forth.
- amino acids for example, lysine, arginine
- the composition may also further contain an additive acceptable for foods or drugs.
- an additive acceptable for foods or drugs examples include inactive carriers (solid and liquid carriers), excipients, surfactants, binders, disintegrating agents, lubricants, dissolving aids, suspending agents, coating agents, colorants, preservatives, buffering agents, pH adjustors, emulsifiers, stabilizers, sweeteners, antioxidants, perfumes, acidulants, and natural substances.
- More specific examples include water, other aqueous solvents, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium alginate, water-soluble dextran, water-soluble dextrin, carboxymethyl starch sodium, pectin, xanthan gum, gum arabic, casein, gelatin, agar, glycerin, propylene glycol, polyethylene glycol, vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin.
- mannitol sorbitol, lactose, sucralose, stevia, aspartame, acesulfame potassium, citric acid, lactic acid, malic acid, tartaric acid, phosphoric acid, acetic acid, fruit juice, vegetable juice, and so forth.
- the pharmaceutical composition of the present invention can be in an arbitrary dosage form suitable for oral administration, for example, solid preparation such as tablet, granule, powder, pill, and capsule, liquid preparation such as solution, suspension, and syrup, gel, aerosol, or the like.
- the food composition of the present invention may be prepared in an arbitrary form such as solid, liquid, mixture, suspension, powder, granule, paste, jelly, gel, and capsule.
- the food composition of the present invention can be made in such an arbitrary form as dairy product, supplement, confectionery, drink, drinkable preparation, seasoning, processed food, daily dish, and soup.
- composition of the present invention may be in the form of milk beverage, soft drink, fermented milk, yogurt, ice cream, tablet, cheese, bread, biscuit, cracker, pizza crust, special formula powdered milk, liquid food, food for sick persons, nutritional food, frozen food, processed food, or the like, or may be in a form for being mixed in drink or food and then ingested, such as granule, powder, paste, and thick solution.
- time of adding EPS of a lactic acid bacterium can be appropriately chosen. Unless the characteristics of EPS of a lactic acid bacterium are not markedly degraded, the time of the addition is not particularly limited. For example, it can be added to the raw materials and mixed in an early stage of the manufacture.
- fermented milk containing EPS can be produced by adding a lactic acid bacterium that produces EPS as a starter to raw material milk, and allowing fermentation so that EPS is produced.
- the composition of the present invention can have an indication describing that the composition can be used for enhancing an immune checkpoint blockade therapy, or an indication describing that ingestion of the composition is recommended for specific subjects.
- the indications may be a direct or indirect indication. Examples of the direct indication include descriptions on tangible articles such as the product itself, package, container, label, and tag, and examples of the indirect indication includes advertising campaign activities using such places or means as web site, shop, pamphlet, exhibition, book, newspaper, magazine, television, radio, postal matter, E-mail, and sound.
- Example 1 yogurt prepared by adding Lactobacillus delbrueckii subsp. bulgaricus OLL1073 R-1 and Streptococcus thermophilus as a lactic starter to a skimmilk powder medium, and allowing fermentation of the skimmilk powder medium for 2.5 hours in a temperature environment of 43° C. was used.
- EPS contained in a culture obtained by culturing the Lactobacillus delbrueckii subsp. bulgaricus OLL1073 R-1 in a 10 mass % skimmilk powder medium was purified. That is, trichloroacetic acid was added at a final concentration of 10 mass % to the aforementioned culture in which cultivation was performed at 37° C.
- the precipitates were dialyzed against MilliQ water by using a dialysis membrane (molecular cutoff, 6 to 8 kDa), nucleic acids and proteins were enzymatically decomposed, and ethanol precipitation was performed again to obtain precipitates.
- the precipitates were dissolved in MilliQ water, and after dialysis is performed again, they were lyophilized to purify EPS.
- Each therapeutic drug (anti-mouse CTLA-4 antibody or anti-mouse PD-1 antibody) was intraperitoneally administered 3 times (150 ⁇ g/animal/time) until 10 days after the tumor transplantation in the case of the CTLA-4 blockade therapy group, or 5 times (240 ⁇ g/animal/time) until 18 days after the tumor transplantation in the case of the PD-1 blockade therapy group.
- mice were dissected 15 days after the tumor transplantation, and the tumor-infiltrating T lymphocytes were analyzed and compared.
- the mice were euthanized at each occasion.
- each of the extracted tumor masses was minced with a scalpel, and incubated (37° C., 1 hour) in the RPMI 1640 medium containing collagenase (Roche) and DNase (Roche) to obtain a single cell suspension.
- These cells were stained with an antibody mix containing fluorescence-labeled anti-mouse CD3 antibody, anti-mouse CD8 antibody, and anti-mouse CCR6 antibody (all from Japan BD), and the tumor-infiltrating T lymphocytes were analyzed by using a flow cytometer (FACS Verse, Japan BD).
- mice of the both groups of the PD-1 blockade therapy group were followed up, individuals in which tumor growth was clearly suppressed during the drug administration period (until 18 days after the tumor transplantation) were observed only in the yogurt-administered mouse group ( FIG. 1 D ).
- a colon 26 single cell suspension (suspension in PBS) was prepared, and 6.0 ⁇ 10 5 cells/200 ⁇ L were subcutaneously transplanted to each of all the mice on the left abdomen using 26G injection hypodermic needle (TERUMO).
- Anti-mouse CTLA-4 antibody was intraperitoneally administered 3 times (150 ⁇ g/animal/time) to all the mice until 10 days after the tumor transplantation.
- follow-up was performed by measuring the tumor volume with a ruler 3 times per week. All the mice were dissected 15 days after the transplantation of tumor.
- EPS 150 ⁇ g/ml was added to cultured cells of the cell strain TG40 (derived from mouse T lymphocytes), and the cells were cultured for 6 hours.
- the medium was prepared by adding fetal bovine serum (FBS) to RPMI at 10 mass percent concentration, and the cells were inoculated to the medium on a plate at a density of 5 ⁇ 10 6 cells/mL, and maintained at 37° C. and 5% CO 2 .
- FBS fetal bovine serum
- the cells were stained with fluorescence-labeled anti-mouse CCR6 antibody, and analyzed by using a flow cytometer (FACS Verse. Japan BD).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The object of the invention is to provide a composition for enhancing an immune checkpoint blockade therapy. A composition forenhancing an immune checkpoint blockade therapy, which contains an exopolysaccharide of a lactic acid bacterium is provided. Preferred examples of the lactic acid bacterium include Lactobacillus bacteria (especially Lactobacillus delbrueckii subsp. bulgaricus OLL1073 R-1).
Description
- The present invention relates to a composition comprising a culture of a lactic acid bacterium for enhancing an immune checkpoint blockade therapy.
- It has been found that many kinds of tumors use an immunosuppression function based on an immune checkpoint molecule in order to avoid attacks from the immune system. The immune checkpoint blockade therapy is a therapy consisting of canceling suppression of activation of immunocytes including T lymphocytes by inhibiting transfer of immunosuppression signals by immune checkpoint molecules, and thereby increasing patient's immune activity to obtain an antitumor effect. As immunity checkpoint blockades (inhibitors), PD-1 (Programmed Death-1) blocking antibody agents, CTLA-4 (Cytotoxic T Lymphocyte-associated Antigen 4) blocking antibody agents, and so forth have been so far approved for specific tumors.
- Uses of the immune checkpoint blockades in combination with other active ingredients are also examined. For example, Patent document 1 discloses a combination of one or more kinds of anticancer antibodies, and a specific immuno-adjuvant compound for treatment of cancer, and describes that this combinatory drug can be administered further in combination with an antibody that blocks an immunosuppression function. Patent document 2 discloses a peptide consisting of a straight chain sequence of nine amino acids as a compound to be used for treatment of a tumor by being administered in combination with, sequentially with, or separately from an immunity checkpoint blockade. Patent document 3 discloses a concomitant use of a compound that blocks an interaction between the signal regulatory protein alpha (SIRPa) and at least one of the ligands thereof (for example, anti-SIRPa antibody) with a second therapeutic drug, which is for use in a treatment of an arbitrary pathological condition that can be improved or prevented by differentiation of myeloid-derived suppressor cells (MDSC) into non-suppressor cells. This patent document describes that the second therapeutic drug can be selected from the group consisting of chemotherapeutic drug, radiotherapy, surgical operation, immunotherapy drug, antibiotic, and probiotics.
- Meanwhile, lactic acid bacteria produce various substances in the fermentation processes thereof, and one class of them is constituted by extracellular polysaccharides (exopolysaccharides. EPSs). There are know n several physiological activities of EPSs of lactic acid bacteria, such as autoimmune disease prevention action (Patent document 4), NK cell activation action (Patent document 5), pneumococcal infection prevention action (Patent document 6), fatigue feeling-improving action (Patent document 7), and action of suppressing acquired immunity hypofunction caused by an anti-influenza drug (Patent document 8).
-
- Patent document 1: Japanese Patent Unexamined Publication (KOKAI) No. 2012-211196
- Patent document 2: Japanese Patent Unexamined Publication (KOKAI) No. 2016-128399
- Patent document 3: Japanese Patent Unexamined Publication (KOHYO) No. 2017-538669
- Patent document 4: Japanese Patent Unexamined Publication (KOKAI) No. 2000-247895
- Patent document 5: Japanese Patent Unexamined Publication (KOKAI) No. 2005-194259
- Patent document 6: International Patent Publication WO2011/065300
- Patent document 7: International Patent Publication WO2015/133638
- Patent document 8: International Patent Publication WO2017/183595
- Since the immune checkpoint blockade therapy retracts tumors by activating the patients' own immunity, the patients suffer from less burden compared with the conventional surgical resection and radiotherapy. If there is a composition that can enhance the effect of this therapy, it is much more desirable.
- When the inventors of the present invention orally administered yogurt produced by fermentation by a Lactobacillus bacterium (Lactobacillus delbrueckii subsp. bulgaricus OLL1073 R-1) or exopoly saccharides obtained from the lactic acid bacterium to colon cancer model mice, the effects of the CTLA-4 blockade therapy and the PD-1 blockade therapy were enhanced, and suppression of tumor growth was observed. Further, more CCR6-positive CD8+T lymphocytes were observed in the subjects. The present invention was accomplished on the basis of such findings.
- The present invention provides the followings.
-
- [1] A composition for enhancing an immune checkpoint blockade therapy, the composition comprising an exopolysaccharide of a lactic acid bacterium.
- [2] The composition according to 1, wherein the immune checkpoint blockade therapy is a CTLA-4 (Cytotoxic T-Lymphocyte-associated Antigen 4) blockade therapy or a PD-1 (Programmed Death-1) blockade therapy.
- [3] The composition according to 1 or 2, wherein the lactic acid bacterium is one classified into the genus Lactobacillus.
- [4] The composition according to any one of 1 to 3, wherein the lactic acid bacterium is one classified into Lactobacillus delbrueckii subsp. bulgaricus.
- [5] The composition according to any one of 1 to 4, which is fermented milk.
- [6] A composition for increasing CCR6-positive CD8+T lymphocytes, the composition comprising an exopolysaccharide of a lactic acid bacterium.
- [7] A non-medical method for enhancing an immune checkpoint blockade therapy, making a subject ingest a composition comprising an effective amount of an exopolysaccharide of a lactic acid bacterium.
- [8] A non-medical method for increasing CCR6-positive CD8+T lymphocytes in a subject, making a subject ingest a composition comprising an effective amount of an exopolysaccharide of a lactic acid bacterium.
- [9] A method for increasing CCR6-positive CD8+T lymphocytes, the method comprising using an exopolysaccharide of a lactic acid bacterium (except for medical practices for humans).
- The present invention also provides the followings.
-
- [10] A method for enhancing an immune checkpoint blockade therapy in a subject, the method comprising (orally) administering an exopolysaccharide of a lactic acid bacterium or a composition comprising the same to a subject (making a subject (orally) ingest an exopolysaccharide of a lactic acid bacterium or a composition comprising the same).
- [11] Use of an exopolysaccharide of a lactic acid bacterium in manufacture of a composition for enhancing an immune checkpoint blockade therapy.
- [12] An exopolysaccharide of a lactic acid bacterium or a composition comprising the same, for use in a method for enhancing an immune checkpoint blockade therapy.
- [13] A non-therapeutic method for enhancing an immune checkpoint blockade therapy in a subject, the method comprising (orally) administering an exopolysaccharide of a lactic acid bacterium or a composition comprising the same to a subject (making a subject (orally) ingest an exopolysaccharide of a lactic acid bacterium or a composition comprising the same).
- [14] Use of an exopolysaccharide of a lactic acid bacterium, which is for enhancing an immune checkpoint blockade therapy.
- [15] A method for increasing CCR6-positive CD8+T lymphocytes in a subject, which comprises the step of (orally) administering an exopolysaccharide of a lactic acid bacterium or a composition comprising the same to a subject (making a subject (orally) ingest an exopolysaccharide of a lactic acid bacterium or a composition comprising the same).
- [16] Use of an exopoly saccharide of a lactic acid bacterium in manufacture of a composition for increasing CCR6-positive CD8+T lymphocytes.
- [17] An exopolysaccharide of a lactic acid bacterium or a composition comprising the same, which is for use in a method for increasing CCR6-positive CD8+T lymphocytes.
- [18] A non-therapeutic method for increasing CCR6-positive CD8+T lymphocytes in a subject, which comprises the step of (orally) administering an exopolysaccharide of a lactic acid bacterium or a composition comprising the same to a subject (making a subject (orally) ingest an exopolysaccharide of a lactic acid bacterium or a composition comprising the same).
- [19] Use of an exopolysaccharide of a lactic acid bacterium, which is for increasing CCR6-positive CD8+T lymphocytes.
- [20] A method for producing a composition for enhancing an immune checkpoint blockade therapy or for increasing CCR6-positive CD8+T lymphocytes, which comprises the step of mixing an exopolysaccharide of a lactic acid bacterium, and a pharmaceutically acceptable additive.
- According to the present invention, an immune checkpoint blockade therapy can be effectively enhanced. According to the present invention. CCR6-positive CD8+T lymphocytes can also be increased.
-
FIG. 1A The tumor volumes observed for the CTLA-4 blockade therapy group (data for all the individuals). Black solid lines indicate the data for the yogurt-administered mice, and gray broken lines indicate the data for the control mince. The Student's t-test was performed for the data obtained at the time of the last tumor volume measurement, and p values were obtained. -
FIG. 1B The tumor volumes observed for the CTLA-4 blockade therapy group (data for the lower half of the individuals arranged in the order of tumor volume, large to small, for both the yogurt-administered group and the control group). Black solid lines indicate the data for the yogurt-administered mice, and gray broken lines indicate the data for the control mice. The Student's t-test was performed for the data obtained at the time of the last tumor volume measurement, and p values were obtained. -
FIG. 1C CCR6-positive ratios of the CD8+T lymphocytes. The results are shown in the form of average f SE. -
FIG. 1D The tumor volumes observed for the PD-1 blockade therapy group. Black solid lines indicate the data for the yogurt-administered mice, and gray broken lines indicate the data for the control mice. -
FIG. 2A The tumor volumes observed for the mice (data for all the individuals). Black solid lines indicate the data for the EPS-administered mice, and gray broken lines indicate the data for the control mice. The Student's t-test was performed for the data obtained at the time of the last tumor volume measurement, and p values were obtained. -
FIG. 2B The tumor volumes observed for the mice (data for the lower half of the individuals arranged in the order of tumor volume, large to small, for both the EPS-administered group and the control group). Black solid lines indicate the data for the EPS-administered mice, and gray broken lines indicate the data for the control mice. The Student's t-test was performed for the data obtained at the time of the last tumor volume measurement, and p values were obtained. -
FIG. 3 CCR6-positive ratios of the TG40 cells (%). In the system containing EPS, the CCR6-positive ratio significantly increased (p<0.001) compared with the control in which EPS was not added (Student's t-test). - Hereafter, the present invention will be explained in detail.
- The present invention relates to a composition for enhancing an immune checkpoint blockade therapy, which uses an exopolysaccharide (EPS) produced by a lactic acid bacterium as an active ingredient.
- The composition of the present invention contains EPS of a lactic acid bacterium as an active ingredient.
- The term lactic acid bacteria is a general term indicating microorganisms that utilize glucose to produce lactic acid at a yield of 50% or higher based on the saccharide, and as for their physiological characteristics, they are gram-positive cocci or bacilli, and show such characteristics as no motility, no sporulation ability, and catalase negativity. From ancient times, lactic acid bacteria have been eaten in every corner of the world as those contained in fermented milk, and so forth, and can be considered to be extremely safe microorganisms. The lactic acid bacteria are classified into a plurality of genera. EPS of a lactic acid bacterium contained in the composition of the present invention is preferably one produced by a Lactobacillus lactic acid bacterium, which is classified into the genus Lactobacillus.
- Examples of the genus Lactobacillus include, for example, those of Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus plantarum, and so forth. Among these genus Lactobacillus, lactic acid bacteria classified into the bulgaricus species (also referred to as bulgaricus bacteria) are preferred for the present invention. Among these genus Lactobacillus Lactobacillus lactic acid bacteria, those classified into Lactobacillus delbrueckii subsp. bulgaricus are more preferred. According to a particularly preferred embodiment, the lactic acid bacterium is Lactobacillus delbrueckii subsp. bulgaricus OLL1073 R-1 strain (accession number FERM BP-10741) (also referred to as “Lactobacillus delbrueckii subsp. bulgaricus R-1 strain”).
- The Lactobacillus delbrueckii subsp. bulgaricus R-1 strain was deposited at the independent administrative agency. National Institute of Technology and Evaluation, International Patent Organism Depository (IPOD, NITE, #120, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba-ken, 292-0818, Japan) as an international deposition based on the provisions of the Budapest Treaty (depositor, Meiji Co., Ltd.; deposition date. Nov. 29, 2006; accession number. FERM BP-10741).
- EPS to be used in the composition of the present invention as an active ingredient is not particularly limited, so long as it is an EPS that is produced by a lactic acid bacterium (preferably a Lactobacillus lactic acid bacterium classified into the genus Lactobacillus) and provides the objective effect. EPSs produced by lactic acid bacteria are structurally classified into homopolysaccharides and heteropolysaccharides (for example, those constituted by galactose and glucose), and may be modified by phosphorylation, sulfation, or the like, and those of both types can be used as the active ingredient of the composition of the present invention. One of the preferred examples is an acidic EPS containing many phosphate groups. Examples of such EPS are EPSs produced by the Lactobacillus delbrueckii subsp. bulgaricus R-1 strain (refer to Patent document 6 mentioned above).
- EPS of a lactic acid bacterium contained in the composition of the present invention may be contained as a lactic acid bacterium fermentation product. The lactic acid bacterium fermentation product may be a fermentation product itself produced by a lactic acid bacterium, or a processed product thereof. The lactic acid bacterium fermentation product may be, for example, fermented milk (specifically, yogurt etc.). Examples of the processed product thereof include, for example, roughly purified product, culture filtrate or culture supernatant obtained from the fermentation product by removing cells using filtration, centrifugation, or membrane separation, concentrate obtained by concentrating the culture filtrate or culture supernatant, and dried product of the concentrate.
- As for the production method of EPS of a lactic acid bacterium, Patent document 6 mentioned above, and so forth can be referred to. When EPS of a lactic acid bacterium is prepared as a lactic acid bacterium fermentation product, fermented milk containing EPS can be produced by adding a lactic acid bacterium that produces EPS as a starter to raw material milk, and allowing fermentation so that EPS is produced in the fermentation product. The conditions for the fermentation, such as type of raw material milk, fermentation temperature, and fermentation time, are not particularly limited, so long as the lactic acid bacterium used can produce EPS, and those skilled in the art can appropriately set them.
- The composition of the present invention can be used in order to enhance an immune checkpoint blockade therapy. The expression of to enhance an immune checkpoint blockade therapy means to make the effect of the immune checkpoint blockade therapy to be obtained earlier, to increase the effect of the immune checkpoint blockade therapy, to increase response rate for the immune checkpoint blockade therapy, to make the effect of the immune checkpoint blockade therapy to be obtained with a lower dose of the immune checkpoint blockade, or the like, when the composition of the present invention is used in combination with the immune checkpoint blockade therapy. Examples of the effect of an immune checkpoint blockade therapy include, for example, shrink of cancer by death of cancer cells (decrease of tumor volume), delay of growth of cancer (suppression of increase of tumor volume), cure of cancer, prevention of metastasis or recurrence of cancer, and death of possible metastasized cancer cells.
- The immune checkpoint molecules constitute a group of molecules that suppress immune responses to self in order to maintain immunological homeostasis, and at the same time, suppress excessive immunoreactions. Although they originally exist in order to suppress excessive activation of the immunocytes including T lymphocytes, and prevent attacks against self, cancer cells utilize them in a carcinogenic process in order to avoid attacks by the immune system and thereby grow. Until now, various immune checkpoint molecules and ligands thereof have been identified.
- Examples of the immune checkpoint molecules include PD-1, CTLA-4, TIM-3, BTLA, and LAG-3/TCR, and the composition of the present invention can be used in a therapy concerning inhibition by any of such immune checkpoint molecules. Especially preferred examples of the therapy include a therapy using a CTLA-4 blockade and a therapy using a PD-1 blockade. Examples of the CTLA-4 blockade include ipilimumab (Yervoy), avelumab, and atezolizumab, and examples of the PD-1 blockade include nivolumab (Opdivo), pembrolizumab (Keytruda), and pembrolizumab. The composition of the present invention can be used for any immune checkpoint blockade therapy using any of these.
- The lowness of response rate for immune checkpoint blockade therapies has constituted a serious problem. The main cause for that is that many checkpoints (brakes) occur until the immune system of patient functions and cancer cells are actually injured. That is, even if one of the brakes can be eliminated with one kind of immunity checkpoint blockade, there are often still other brakes, and therefore sufficient curative effect cannot be observed in many cases. The composition of the present invention has an action of increasing a certain kind of cytotoxic T lymphocytes (CCR6-positive CD8+T lymphocytes). Therefore, it is considered that, only by eliminating one brake of cytotoxic T lymphocytes, such as CTLA-4 and PD-1, among the checkpoints of various immunocytes, the effect was markedly increased, and the curative effect was clearly observed. This leads that the composition of the present invention can also be expected to compensate the lowness of the response rate for immune checkpoint blockade therapies.
- Examples of cancers to which immune checkpoint blockade therapy is applied include malignant melanoma, non-small cell lung cancer, renal cell cancer, Hodgkin's lymphoma, head and neck cancer, gastric cancer, urinary tract epithelial cancer, Merkel cell cancer, and so forth. The composition of the present invention can be used for an immune checkpoint blockade therapy for any of these.
- According to the study of the inventors of the present invention, when the composition of the present invention was administered, increase in CCR6-positive CD8+T lymphocytes was observed in a target tumor, and growth of the tumor was suppressed. Further, when T lymphocytes-derived cell strain TG40 was cultured with EPS, CCR6-positive ratio increased compared with the control not using EPS. These results suggested a possibility that EPS would directly increase CCR6-positive ratio of T lymphocytes. That is, it was found that the composition of the present invention has an action of helping the action of CCR6-positive CD8+T lymphocytes to recognize and kill cells as foreign matter for the subject (cancer cells, virus-infected cells, etc.) (for example, increasing the T lymphocytes, promoting guidance to foreign matter, etc.). Therefore, the composition of the present invention can be used for increasing CCR6-positive CD8+T lymphocytes in the body of a subject, and it can be used for increasing CCR6-positive CD8+T lymphocytes especially in a tumor in the body of the subject. The CCR6-positive ratio means a ratio of CCR6-positive cells among T lymphocytes, unless especially indicated. The CCR6-positive ratio can be obtained as (number of CD3+, CD8+, and CCR6-positive cells)/(number of CD3+ and CD8+ cells), and for an experiment system using TG40, the CCR6-positive ratio can be obtained as (number of CCR6-positive cells)/(total number of TG40 cells).
- The composition of the present invention can be used even for a case that the immune checkpoint blockade therapy is carried out together with another therapy for treatment of cancer. Examples of such another therapy include operation (surgical treatment), therapy using a drug other than immune checkpoint blockade (for example, antimetabolite, alkylating agent, anticancerous antibiotic, microtubule inhibitor, etc.), radiotherapy, hematopoietic stem cell transplantation after a pre-transplantation treatment consisting of massive chemotherapy, systemic radiotherapy, or the like, immunotherapy other than immune checkpoint blockade therapy (for example, cytokine therapy, administration of an immunostimulator, immunocyte transplantation, etc.), alternative therapy for cancer using health food or supplement, and so forth.
- The composition of the present invention can be in the form of a food composition or pharmaceutical composition. Food and drug are not limited to those for humans, and may be those for animals other than human, unless especially indicated. The food may be a common food, functional food, or nutritional composition, or a therapeutic diet (diet for the purpose of treatment, for which a medical practitioner writes a dietary prescription, and which is cooked by a dietitian or the like according to the prescription), dietetic food, ingredient-modified food, care food, or treatment-supporting food, unless especially indicated. The food is not limited to a solid food, but it may be a food in the form of liquid, for example, drink, drinkable preparation, liquid food, or soup, unless especially indicated. Functional food refers to a food that can give a predetermined functionality to a living body, and includes health foods at large, such as foods for specified health uses (abbreviated as “Tokuho” in Japanese, including conditional foods for specified health use), foods with function claims, foods with health claims including foods with nutrient function claims, foods for special dietary uses, supplements (for example, those of various kinds of dosage forms such as tablet, coated tablet, sugar-coated tablet, capsule and solution), and cosmetic food (for example, diet foods). In the present invention, the “functional foods” include health foods to which the health claim based on the food standards of CODEX (JOINT FAO/WHO FOOD STANDARDS PROGRAMME CODEX ALIMENTARIUS COMMISSION) is applied.
- The composition of the present invention is suitable to be ingested by or administered to a subject who or which receives an immune checkpoint blockade therapy, or a subject who or which is planned to receive an immune checkpoint blockade therapy.
- Although the composition of the present invention may be administered parenterally, for example, by tube administration (by gastric fistula, cecal fistula, or the like), or may be administered nasally or orally, it is preferably orally administered.
- Content of EPS of a lactic acid bacterium in the composition of the present invention may be such an amount that the objective effect can be exhibited. Although the dose or ingestion amount of the composition can be appropriately determined in consideration of various factors such as age, weight, and condition of the subject, the daily administration or ingestion amount of EPS of a lactic acid bacterium may be, for example, 0.1 mg or larger, and it is preferably 0.6 mg or larger, more preferably 3 mg or larger. No matter how the minimum daily amount of EPS is defined, the maximum daily amount of EPS may be 480 mg or smaller, and it is preferably 360 mg or smaller, more preferably 180 mg or smaller, particularly preferably 90 mg or smaller.
- The amount of EPS of a lactic acid bacterium per one time of administration or meal, i.e., dose of EPS for single administration or meal, may be, for example, 0.03 mg or larger, and it is preferably 0.2 mg or larger, more preferably 1 mg or larger. No matter how the minimum amount of EPS for single administration or meal is defined, the maximum amount of the same may be 160 mg or smaller, and it is preferably 120 mg or smaller, more preferably 60 mg or smaller, particularly preferably 30 mg or smaller.
- When fermented milk is used as EPS of a lactic acid bacterium of the composition of the present invention, the daily amount of the fermented milk may be, for example, 10 g or larger, and it is preferably 30 g or larger, more preferably 60 g or larger. No matter how the minimum daily amount of fermented milk is defined, the maximum amount of the same may be, for example, 1500 g or smaller, and it is preferably 1200 g or smaller, more preferably 600 g or smaller.
- The amount of fermented milk for one time of administration or meal. i.e., dose for single administration or meal, may be, for example, 3 g or larger, and it is preferably 10 g or larger, more preferably 20 g or larger. No matter how the minimum amount of fermented milk for one time of administration or meal is defined, the maximum amount of the same may be, for example, 800 g or smaller, and it is preferably 400 g or smaller, more preferably 200 g or smaller.
- The composition may be administered or ingested one time per day, or may be administered a plurality of times per day, for example, at every meal, i.e., three times a day. The composition uses EPS of a lactic acid bacterium, which has been abundantly used in foods for many years, as the active ingredient. Therefore, the composition of the present invention can be ingested repetitively, or over a long period of time, and it may be continuously administered or ingested over, for example, one week or longer, preferably four weeks or longer.
- The composition of the present invention may contain another active ingredient or nutritional ingredient acceptable for foods or drugs. Examples of such an ingredient include amino acids (for example, lysine, arginine, glycine, alanine, glutamic acid, leucine, isoleucine, and valine), saccharides (glucose, sucrose, fructose, maltose, trehalose, erythritol, maltitol, paratinose, xylitol, and dextrin), electrolytes (for example, sodium, potassium, calcium and magnesium), vitamins (for example, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, biotin, folic acid, pantothenic acid, and nicotinic acid), minerals (for example, copper, zinc, iron, cobalt, and manganese), antibiotics, dietary fibers, proteins, lipids, and so forth.
- The composition may also further contain an additive acceptable for foods or drugs. Examples of such an additive include inactive carriers (solid and liquid carriers), excipients, surfactants, binders, disintegrating agents, lubricants, dissolving aids, suspending agents, coating agents, colorants, preservatives, buffering agents, pH adjustors, emulsifiers, stabilizers, sweeteners, antioxidants, perfumes, acidulants, and natural substances. More specific examples include water, other aqueous solvents, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium alginate, water-soluble dextran, water-soluble dextrin, carboxymethyl starch sodium, pectin, xanthan gum, gum arabic, casein, gelatin, agar, glycerin, propylene glycol, polyethylene glycol, vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin. mannitol, sorbitol, lactose, sucralose, stevia, aspartame, acesulfame potassium, citric acid, lactic acid, malic acid, tartaric acid, phosphoric acid, acetic acid, fruit juice, vegetable juice, and so forth.
- The pharmaceutical composition of the present invention can be in an arbitrary dosage form suitable for oral administration, for example, solid preparation such as tablet, granule, powder, pill, and capsule, liquid preparation such as solution, suspension, and syrup, gel, aerosol, or the like.
- The food composition of the present invention may be prepared in an arbitrary form such as solid, liquid, mixture, suspension, powder, granule, paste, jelly, gel, and capsule. The food composition of the present invention can be made in such an arbitrary form as dairy product, supplement, confectionery, drink, drinkable preparation, seasoning, processed food, daily dish, and soup. More specifically, the composition of the present invention may be in the form of milk beverage, soft drink, fermented milk, yogurt, ice cream, tablet, cheese, bread, biscuit, cracker, pizza crust, special formula powdered milk, liquid food, food for sick persons, nutritional food, frozen food, processed food, or the like, or may be in a form for being mixed in drink or food and then ingested, such as granule, powder, paste, and thick solution.
- In the manufacture of the composition of the present invention, time of adding EPS of a lactic acid bacterium can be appropriately chosen. Unless the characteristics of EPS of a lactic acid bacterium are not markedly degraded, the time of the addition is not particularly limited. For example, it can be added to the raw materials and mixed in an early stage of the manufacture. Alternatively, when the composition of the present invention is implemented as fermented milk, fermented milk containing EPS can be produced by adding a lactic acid bacterium that produces EPS as a starter to raw material milk, and allowing fermentation so that EPS is produced.
- The composition of the present invention can have an indication describing that the composition can be used for enhancing an immune checkpoint blockade therapy, or an indication describing that ingestion of the composition is recommended for specific subjects. The indications may be a direct or indirect indication. Examples of the direct indication include descriptions on tangible articles such as the product itself, package, container, label, and tag, and examples of the indirect indication includes advertising campaign activities using such places or means as web site, shop, pamphlet, exhibition, book, newspaper, magazine, television, radio, postal matter, E-mail, and sound.
- Hereafter, the present invention will be more specifically explained with reference to examples. However, the technical scope of the present invention is not limited by these examples.
- In Example 1, yogurt prepared by adding Lactobacillus delbrueckii subsp. bulgaricus OLL1073 R-1 and Streptococcus thermophilus as a lactic starter to a skimmilk powder medium, and allowing fermentation of the skimmilk powder medium for 2.5 hours in a temperature environment of 43° C. was used. In Examples 2 and 3, EPS contained in a culture obtained by culturing the Lactobacillus delbrueckii subsp. bulgaricus OLL1073 R-1 in a 10 mass % skimmilk powder medium was purified. That is, trichloroacetic acid was added at a final concentration of 10 mass % to the aforementioned culture in which cultivation was performed at 37° C. for 18 hours, denatured proteins were removed, cold ethanol was added to the culture, and the mixture was left standing at 4° C. for 2 hours to obtain precipitates containing EPS. The precipitates were dialyzed against MilliQ water by using a dialysis membrane (molecular cutoff, 6 to 8 kDa), nucleic acids and proteins were enzymatically decomposed, and ethanol precipitation was performed again to obtain precipitates. The precipitates were dissolved in MilliQ water, and after dialysis is performed again, they were lyophilized to purify EPS.
- Thirty-two in total of 7 weeks old BALB/c male mice (Charles River Japan) were divided into groups of control mice (n=16) and yogurt administration mice (n=16). To the control mice and yogurt administration mice, 400 μL/animal of 10% (w/h) skimmilk powder solution and the yogurt were orally administered, respectively. The oral administration was carried out once a day every day until the day before the dissection. The amount of EPS contained in 400 μL of the yogurt was 28 μg as determined by HPLC using a corona charged particle detector.
- On the day of the start of the oral administration, there was prepared a suspension (suspension in PBS) of the colon 26 single cells, which are cells of mouse colon cancer cell strain, and 6.0×105 cells/200 μL were subcutaneously transplanted to each of all the mice on the left abdomen using 26G injection hypodermic needle (TERUMO). The mice of each group (n=16) were further divided into 2 groups according to the treatment method, one of which was CTLA-4 blockade therapy group (n=8), and the other of which was PD-1 blockade therapy group (n=8). Each therapeutic drug (anti-mouse CTLA-4 antibody or anti-mouse PD-1 antibody) was intraperitoneally administered 3 times (150 μg/animal/time) until 10 days after the tumor transplantation in the case of the CTLA-4 blockade therapy group, or 5 times (240 μg/animal/time) until 18 days after the tumor transplantation in the case of the PD-1 blockade therapy group.
- Follow-up was performed by measuring the tumor volume with a ruler 3 times per week. In the case of the CTLA-4 blockade therapy group, the mice were dissected 15 days after the tumor transplantation, and the tumor-infiltrating T lymphocytes were analyzed and compared. In the case of the PD-1 blockade therapy group, when the tumor volume exceeded 2000 mm3, which was defined as a humane endpoint, the mice were euthanized at each occasion.
- In the CTLA-4 blockade therapy group, significant difference was not observed in comparison of the tumor volumes of the mice of the both groups observed immediately before the dissection (
FIG. 1A ). However, when there were compared the tumor volumes of the mice of half numbers of the groups, which showed lower tumor volumes, and thus in which the therapeutic effect of the drug was considered to be observed, the tumor volumes of the yogurt-administered mice were significantly smaller than those of the control mice (FIG. 1B ). - Further, each of the extracted tumor masses was minced with a scalpel, and incubated (37° C., 1 hour) in the RPMI 1640 medium containing collagenase (Roche) and DNase (Roche) to obtain a single cell suspension. These cells were stained with an antibody mix containing fluorescence-labeled anti-mouse CD3 antibody, anti-mouse CD8 antibody, and anti-mouse CCR6 antibody (all from Japan BD), and the tumor-infiltrating T lymphocytes were analyzed by using a flow cytometer (FACS Verse, Japan BD).
- As a result, it was found that the CCR6-positive CD8+T lymphocytes significantly increased in the yogurt-administered mice (
FIG. 1C ). It was confirmed by this result that the cell-mediated immunity was activated in the cancer tissues to suppress the growth of the tumor in the yogurt-administered mice. - When the tumor growth of the mice of the both groups of the PD-1 blockade therapy group was followed up, individuals in which tumor growth was clearly suppressed during the drug administration period (until 18 days after the tumor transplantation) were observed only in the yogurt-administered mouse group (
FIG. 1D ). - The above results revealed that oral ingestion of yogurt of the present invention or EPS contained in it enhances the therapeutic effect of the CTLA-4 blockade therapy or the PD-1 blockade therapy.
- Twenty-four in total of 7 weeks old BALB/c male mice (Charles River Japan) were divided into groups of control mice (n=12) and EPS administration mice (n=12). The control mice and yogurt administration mice were allowed to freely drink distilled water and an EPS aqueous solution (25 μg/ml), respectively (it was recognized that the mice drunk about 4 to 8 mL/day of water or the solution), until the day of dissection.
- On the day of the start of the free drinking, a colon 26 single cell suspension (suspension in PBS) was prepared, and 6.0×105 cells/200 μL were subcutaneously transplanted to each of all the mice on the left abdomen using 26G injection hypodermic needle (TERUMO). Anti-mouse CTLA-4 antibody was intraperitoneally administered 3 times (150 μg/animal/time) to all the mice until 10 days after the tumor transplantation. Follow-up was performed by measuring the tumor volume with a ruler 3 times per week. All the mice were dissected 15 days after the transplantation of tumor.
- When the tumor volumes of the mice of the both groups observed immediately before the dissection day were compared, it was found that the tumor volumes observed for the EPS administration group were significantly smaller (
FIG. 2A ), and when the tumor volumes of the mice of half numbers of the respective groups showing smaller tumor volumes were compared, more significant tumor growth suppression was observed for the same group (FIG. 2B ). - The above results revealed that oral ingestion of yogurt of the present invention or EPS contained in it enhances the therapeutic effect of the CTLA-4 blockade therapy or the PD-1 blockade therapy.
- EPS (150 μg/ml) was added to cultured cells of the cell strain TG40 (derived from mouse T lymphocytes), and the cells were cultured for 6 hours. The medium was prepared by adding fetal bovine serum (FBS) to RPMI at 10 mass percent concentration, and the cells were inoculated to the medium on a plate at a density of 5×106 cells/mL, and maintained at 37° C. and 5% CO2.
- The cells were stained with fluorescence-labeled anti-mouse CCR6 antibody, and analyzed by using a flow cytometer (FACS Verse. Japan BD).
- As a result, it was found that CCR6-positive ratio significantly increased (p<0.001) in the system to which EPS was added compared with the control in which EPS was not added (Student's t-test,
FIG. 3 ). This result suggested that EPS directly increases CCR6-positive CD8+T lymphocytes in an environment other than intratumoral environment.
Claims (9)
1. A composition for enhancing an immune checkpoint blockade therapy, the composition comprising an exopolysaccharide of a lactic acid bacterium.
2. The composition according to claim 1 , wherein the immune checkpoint blockade therapy is a CTLA-4 (Cytotoxic T-Lymphocyte-associated Antigen 4) blockade therapy or a PD-1 (Programmed Death-1) blockade therapy.
3. The composition according to claim 1 , wherein the lactic acid bacterium is one classified into the genus Lactobacillus.
4. The composition according to claim 1 , wherein the lactic acid bacterium is one classified into Lactobacillus delbrueckii subsp. bulgaricus.
5. The composition according to claim 1 , which is fermented milk.
6. A composition for increasing CCR6-positive CD8+T lymphocytes, the composition comprising an exopolysaccharide of a lactic acid bacterium.
7. A non-therapeutic method for enhancing an immune checkpoint blockade therapy, the method comprising
making a subject ingest a composition comprising an effective amount of an exopolysaccharide of a lactic acid bacterium.
8. A non-therapeutic method for increasing CCR6-positive CD8+T lymphocytes in a subject, the method comprising
making a subject ingest a composition comprising an effective amount of an exopolysaccharide of a lactic acid bacterium.
9. A method for increasing CCR6-positive CD8+T lymphocytes, the method comprising
using an exopolysaccharide of a lactic acid bacterium (except for medical practices for humans).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/236,035 US20230390348A1 (en) | 2018-06-14 | 2023-08-21 | Composition for enhancing immune checkpoint blockade therapy |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-113758 | 2018-06-14 | ||
JP2018113758 | 2018-06-14 | ||
PCT/JP2019/023470 WO2019240218A1 (en) | 2018-06-14 | 2019-06-13 | Composition for promoting immune checkpoint inhibition therapy |
US202017058329A | 2020-11-24 | 2020-11-24 | |
US18/236,035 US20230390348A1 (en) | 2018-06-14 | 2023-08-21 | Composition for enhancing immune checkpoint blockade therapy |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/023470 Division WO2019240218A1 (en) | 2018-06-14 | 2019-06-13 | Composition for promoting immune checkpoint inhibition therapy |
US17/058,329 Division US11759485B2 (en) | 2018-06-14 | 2019-06-13 | Composition for enhancing immune checkpoint blockade therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230390348A1 true US20230390348A1 (en) | 2023-12-07 |
Family
ID=68841863
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/058,329 Active US11759485B2 (en) | 2018-06-14 | 2019-06-13 | Composition for enhancing immune checkpoint blockade therapy |
US18/236,035 Pending US20230390348A1 (en) | 2018-06-14 | 2023-08-21 | Composition for enhancing immune checkpoint blockade therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/058,329 Active US11759485B2 (en) | 2018-06-14 | 2019-06-13 | Composition for enhancing immune checkpoint blockade therapy |
Country Status (4)
Country | Link |
---|---|
US (2) | US11759485B2 (en) |
JP (1) | JP7490554B2 (en) |
CN (1) | CN112334141A (en) |
WO (1) | WO2019240218A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017167213A1 (en) * | 2016-03-30 | 2017-10-05 | Microbio Co., Ltd. | Combined cancer therapy with immune checkpoint modulators and fermentation products by symbiotic microbiota |
CN112877268A (en) * | 2021-04-22 | 2021-06-01 | 上海耀旦生物科技有限公司 | Lactobacillus casei strain for enhancing treatment effect of immune checkpoint inhibitor and application thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3995733B2 (en) | 1995-07-17 | 2007-10-24 | 明治乳業株式会社 | Immunostimulatory composition |
JP3017493B1 (en) | 1999-02-25 | 2000-03-06 | 明治乳業株式会社 | Autoimmune disease prevention composition |
JP2004317656A (en) | 2003-04-14 | 2004-11-11 | Fuji Photo Film Co Ltd | Heat developable photosensitive material |
JP5177728B2 (en) | 2003-12-12 | 2013-04-10 | 株式会社明治 | NK cell activator |
CN103285392A (en) | 2005-04-26 | 2013-09-11 | 卫材R&D管理株式会社 | Compositions for cancer immunotherapy and use thereof |
JP2008245576A (en) * | 2007-03-30 | 2008-10-16 | Yotsuba Nyugyo Kk | Lactobacillus expectable to have immunomodulating action and extracellular polysaccharide |
JP2010130954A (en) * | 2008-12-04 | 2010-06-17 | Glico Dairy Products Co Ltd | Lactic acid bacterium for enhancing intestinal tract immunity, product containing lactic acid bacterium for enhancing intestinal tract immunity using the same and method for producing the same |
WO2011043665A1 (en) * | 2009-10-07 | 2011-04-14 | Stichting Top Institute Food And Nutrition | Method for improved fermentation |
SG10201407677WA (en) | 2009-11-25 | 2015-01-29 | Meiji Co Ltd | Antiviral agent and food/beverage composition |
JPWO2015133638A1 (en) | 2014-03-07 | 2017-04-06 | 株式会社明治 | Pneumococcal infection preventive agent |
US20190282632A1 (en) | 2014-10-23 | 2019-09-19 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
JP6767096B2 (en) | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | Combination of immune checkpoint inhibitors |
US20180132498A1 (en) * | 2015-04-16 | 2018-05-17 | Glanbia Nutritionals (Ireland) Ltd. | Method for Making a Fermented Whey Protein Product |
RU2017141448A (en) | 2015-06-01 | 2019-07-15 | Зэ Юниверсити Оф Чикаго | TREATMENT OF CANCER BY MANIPULATION WITH COMMENSAL MICROFLORA |
BR112017026564B1 (en) | 2015-06-15 | 2022-05-03 | 4D Pharma Research Limited | BACTERIAL CELLS, USES, AND COMPOSITION |
WO2017167213A1 (en) * | 2016-03-30 | 2017-10-05 | Microbio Co., Ltd. | Combined cancer therapy with immune checkpoint modulators and fermentation products by symbiotic microbiota |
JP7248426B2 (en) | 2016-04-20 | 2023-03-29 | 株式会社明治 | Fermented milk for improving subjective symptoms of summer fatigue |
JP6396948B2 (en) * | 2016-06-16 | 2018-09-26 | 株式会社明治 | Streptococcus thermophilus fermentation promoter |
JP6829430B2 (en) * | 2016-10-20 | 2021-02-10 | 京都府 | Manufacturing method of lactic acid fermented soymilk |
US11167008B2 (en) * | 2016-11-23 | 2021-11-09 | Vaxiion Therapeutics, Llc | Immunomodulatory and oncolytic minicells and methods of use |
WO2018222969A1 (en) * | 2017-06-02 | 2018-12-06 | Board Of Regents, The University Of Texas System | Specific bacterial species and metabolite that improves immune checkpoint inhibitor therapy efficacy |
EP3737395A4 (en) * | 2018-01-09 | 2021-09-29 | Microbio Co., Ltd. | Method of activating tumor-infiltrating lymphocytes (tils) |
WO2019009438A1 (en) * | 2018-09-21 | 2019-01-10 | 株式会社日本自然発酵 | Immune checkpoint inhibitor |
-
2019
- 2019-06-13 CN CN201980039616.0A patent/CN112334141A/en active Pending
- 2019-06-13 JP JP2020525651A patent/JP7490554B2/en active Active
- 2019-06-13 WO PCT/JP2019/023470 patent/WO2019240218A1/en active Application Filing
- 2019-06-13 US US17/058,329 patent/US11759485B2/en active Active
-
2023
- 2023-08-21 US US18/236,035 patent/US20230390348A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7490554B2 (en) | 2024-05-27 |
US20210213077A1 (en) | 2021-07-15 |
CN112334141A (en) | 2021-02-05 |
US11759485B2 (en) | 2023-09-19 |
JPWO2019240218A1 (en) | 2021-07-01 |
WO2019240218A1 (en) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230390348A1 (en) | Composition for enhancing immune checkpoint blockade therapy | |
JP5031249B2 (en) | Bacteria-containing composition having anti-inflammatory effect | |
EP3858368B1 (en) | Antitumor effect potentiator | |
JP5300772B2 (en) | Novel lactic acid bacteria and pharmaceuticals, foods and drinks, and feeds containing the novel lactic acid bacteria | |
KR101492650B1 (en) | Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor | |
CN109966320B (en) | Application of bacillus coagulans in preparation of sensitization preparation for inducing anti-tumor immunity and immune checkpoint inhibitor | |
JP5337535B2 (en) | NK activity enhancer | |
WO2012027032A1 (en) | Method for stimulating foxp3+ regulatory t cell expression of cd39 | |
CN112351693A (en) | Anti-influenza virus agent for inhibiting severe influenza | |
JP2015070855A (en) | Fermented milk production method and antiviral agent production method | |
WO2020067422A1 (en) | Composition for activating t cells | |
JP5550802B2 (en) | Composition containing melon extract having immunomodulating action | |
JP4064515B2 (en) | IL-12 production inducing composition | |
EP3479836B1 (en) | Cartilage regeneration facilitating composition | |
KR20220091427A (en) | A composition for improving, preventing and treating autoimmune diseases comprising extracellular vesicles from Lactobacillus sakei | |
JP2021080187A (en) | Composition for inhibiting viral replication | |
US20220022516A1 (en) | Composition for Suppressing Norovirus Infection | |
CN113018308A (en) | Composition for regulating immune balance | |
US20220387522A1 (en) | Composition for enhancing or improving immune system comprising bifidobacterium bifidum | |
WO2024043298A1 (en) | Composition for improving intestinal bacterial flora | |
TW202421178A (en) | Composition for improving intestinal metabolites composition comprising lactobacillus plantarum | |
KR20240040601A (en) | Composition for improving intestinal metabolites composition comprising Lactobacillus plantarum | |
TW202304470A (en) | Muscle synthesis enhancing agent and p70s6k protein phosphorylation enhancing agent | |
KR20240040656A (en) | Composition for improving intestinal metabolites composition comprising Lactobacillus plantarum | |
WO2023079036A1 (en) | Probiotic composition comprising a lactobacillus salivarius strain, a lactobacillus camelliae strain and a bifidobacterium ruminantium strain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |